Bone Biologics completed $5.9 million of financing.
Here are three things to know:
1. The round included $3.9 million in equity and a $2 million credit facility.
2. Bone Biologics will use the proceeds for working capital, protein development, regulatory and clinical expenses and to repay $600,000 in debt.
3. The company is developing the recombinant human protein growth factor NELL-1 bone graft substitute for spinal fusion.
More articles on biologics:
Viscogliosi Brothers to purchase Bioventus' BMP development program: 5 insights
3 things to know about Ortho RTi
23 developments in spine & orthopedic biologics research in 2018